Back to Search Start Over

CSF levels of apolipoprotein C1 and autotaxin found to associate with neuropathic pain and fibromyalgia

Authors :
Lind, Anne-Li
Just, David
Mikus, Maria
Fredolini, Claudia
Ioannou, Marina
Gerdle, Björn
Ghafouri, Bijar
Bäckryd, Emmanuel
Tanum, Lars
Gordh, Torsten
Manberg, Anna
Lind, Anne-Li
Just, David
Mikus, Maria
Fredolini, Claudia
Ioannou, Marina
Gerdle, Björn
Ghafouri, Bijar
Bäckryd, Emmanuel
Tanum, Lars
Gordh, Torsten
Manberg, Anna
Publication Year :
2019

Abstract

Objective: Neuropathic pain and fibromyalgia are two common and poorly understood chronic pain conditions that lack satisfactory treatments, cause substantial suffering and societal costs. Today, there are no biological markers on which to base chronic pain diagnoses, treatment choices or to understand the pathophysiology of pain for the individual patient. This study aimed to investigate cerebrospinal fluid (CSF) protein profiles potentially associated with fibromyalgia and neuropathic pain. Methods: CSF samples were collected from 25 patients with neuropathic pain (two independent sets, n=14 patients for discovery, and n=11 for verification), 40 patients with fibromyalgia and 134 controls without neurological disease from two different populations. CSF protein profiling of 55 proteins was performed using antibody suspension bead array technology. Results: We found increased levels of apolipoprotein C1 (APOC1) in CSF of neuropathic pain patients compared to controls and there was a trend for increased levels also in fibromyalgia patients. In addition, levels of ectonucleotide pyrophosphatase family member 2 (ENPP2, also referred to as autotaxin) were increased in the CSF of fibromyalgia patients compared to all other groups including patients with neuropathic pain. Conclusion: The increased levels of APOC1 and ENPP2 found in neuropathic pain and fibromyalgia patients may shed light on the underlying mechanisms of these conditions. Further investigation is required to elucidate their role in maintaining pain and other main symptoms of these disorders.<br />Funding Agencies|Swedish Governmental Agency for Innovation SystemsVinnova; Swedish Research Council (Vetenskapsradet)Swedish Research Council; Uppsala University; KTH Center for Applied Precision Medicine (KCAP); Marie-Curie fellowship from the INSENS/FP7-PEOPLE-2013European Union (EU) [607616]; NEURO Sweden; AFA Insurance; ALF Grants, Region Ostergotland

Details

Database :
OAIster
Notes :
application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1234338223
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.2147.JPR.S215348